Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab

Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab

Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Croh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Petkau JM, Eksteen B
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Vedolizumab
Ulcerative Colitis
Crohn's disease
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/16d54277c0ca45cd9a766de82cb513b8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:16d54277c0ca45cd9a766de82cb513b8
record_format dspace
spelling oai:doaj.org-article:16d54277c0ca45cd9a766de82cb513b82021-12-02T05:10:51ZSelective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab1177-5491https://doaj.org/article/16d54277c0ca45cd9a766de82cb513b82016-03-01T00:00:00Zhttps://www.dovepress.com/selective-biologics-for-ulcerative-colitis-and-crohn39s-disease-ndash--peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn's disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogenous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability in environmental exposures. Despite this variability, there has been relatively few efficacious therapies for particularly moderate-to-severe IBD. Treatment has been dominated by antitumor necrosis alpha agents with significant success but equally potentially serious adverse events. Therapeutic targeting of leucocyte trafficking has emerged as a viable alternative therapy, with vedolizumab being the lead compound. This review focuses primarily on its biological function as a selective gut immunotherapy, its safety and efficacy, and its emerging role as a mainstream therapy in managing IBD. Keywords: adhesion molecule antagonist, anti-α4β7 integrin, inflammatory bowel disease, leukocyte trafficking, monoclonal antibody, selective gut immunotherapy, tumor necrosis factor alphaPetkau JMEksteen BDove Medical PressarticleVedolizumabUlcerative ColitisCrohn's diseaseMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 33-52 (2016)
institution DOAJ
collection DOAJ
language EN
topic Vedolizumab
Ulcerative Colitis
Crohn's disease
Medicine (General)
R5-920
spellingShingle Vedolizumab
Ulcerative Colitis
Crohn's disease
Medicine (General)
R5-920
Petkau JM
Eksteen B
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
description Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn's disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogenous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability in environmental exposures. Despite this variability, there has been relatively few efficacious therapies for particularly moderate-to-severe IBD. Treatment has been dominated by antitumor necrosis alpha agents with significant success but equally potentially serious adverse events. Therapeutic targeting of leucocyte trafficking has emerged as a viable alternative therapy, with vedolizumab being the lead compound. This review focuses primarily on its biological function as a selective gut immunotherapy, its safety and efficacy, and its emerging role as a mainstream therapy in managing IBD. Keywords: adhesion molecule antagonist, anti-α4β7 integrin, inflammatory bowel disease, leukocyte trafficking, monoclonal antibody, selective gut immunotherapy, tumor necrosis factor alpha
format article
author Petkau JM
Eksteen B
author_facet Petkau JM
Eksteen B
author_sort Petkau JM
title Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
title_short Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
title_full Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
title_fullStr Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
title_full_unstemmed Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
title_sort selective biologics for ulcerative colitis and crohn's disease – clinical utility of vedolizumab
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/16d54277c0ca45cd9a766de82cb513b8
work_keys_str_mv AT petkaujm selectivebiologicsforulcerativecolitisandcrohn39sdiseasendashclinicalutilityofvedolizumab
AT eksteenb selectivebiologicsforulcerativecolitisandcrohn39sdiseasendashclinicalutilityofvedolizumab
_version_ 1718400515206807552

Ejemplares similares